BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25545309)

  • 21. Anti-Müllerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome.
    El-Mazny A; Abou-Salem N
    Gynecol Endocrinol; 2013 Sep; 29(9):826-9. PubMed ID: 23855354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome.
    Carlsen SM; Vanky E; Fleming R
    Hum Reprod; 2009 Jul; 24(7):1732-8. PubMed ID: 19342396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of supervised aerobic training on the levels of anti-Mullerian hormone and adiposity measures in women with normo-ovulatory and polycystic ovary syndrome.
    Al-Eisa E; Gabr SA; Alghadir AH
    J Pak Med Assoc; 2017 Apr; 67(4):499-507. PubMed ID: 28420905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome.
    Nardo LG; Yates AP; Roberts SA; Pemberton P; Laing I
    Hum Reprod; 2009 Nov; 24(11):2917-23. PubMed ID: 19617605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum anti-Müllerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus.
    Łebkowska A; Adamska A; Karczewska-Kupczewska M; Nikołajuk A; Otziomek E; Milewski R; Górska M; Wołczyński S; Kowalska I
    Metabolism; 2016 May; 65(5):804-811. PubMed ID: 26961579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
    Vosnakis C; Georgopoulos NA; Armeni AK; Papadakis E; Roupas ND; Katsikis I; Panidis D
    Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):185-9. PubMed ID: 22579228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
    Tremellen K; Zander-Fox D
    Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
    Vosnakis C; Georgopoulos NA; Rousso D; Mavromatidis G; Katsikis I; Roupas ND; Mamali I; Panidis D
    Gynecol Endocrinol; 2013 Mar; 29(3):242-5. PubMed ID: 23194076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predictive value of anti-Mullerian hormone levels in serum and follicle fluid for IVF-ET outcomes in patients with polycystic ovarian syndrome].
    Chen X; Yin M; Ye D; He Y; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):546-9. PubMed ID: 23644117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
    Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
    Eilertsen TB; Vanky E; Carlsen SM
    Hum Reprod; 2012 Aug; 27(8):2494-502. PubMed ID: 22693172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A functional anti-mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients.
    Kevenaar ME; Laven JS; Fong SL; Uitterlinden AG; de Jong FH; Themmen AP; Visser JA
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1310-6. PubMed ID: 18230658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
    Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
    Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome.
    Somunkiran A; Yavuz T; Yucel O; Ozdemir I
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):196-201. PubMed ID: 17335955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron stores and obesity are negatively associated with ovarian volume and anti-Müllerian hormone levels in women with polycystic ovary syndrome.
    Yang JH; Chou CH; Yang WS; Ho HN; Yang YS; Chen MJ
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):686-92. PubMed ID: 26700986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.
    Dewailly D; Lujan ME; Carmina E; Cedars MI; Laven J; Norman RJ; Escobar-Morreale HF
    Hum Reprod Update; 2014; 20(3):334-52. PubMed ID: 24345633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Müllerian hormone, testosterone and free androgen index following the dose-adjusted unilateral diathermy in women with polycystic ovary syndrome.
    Sunj M; Canic T; Jeroncic A; Karelovic D; Tandara M; Juric S; Palada I
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():163-9. PubMed ID: 24965999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve.
    Uncu G; Kasapoglu I; Ozerkan K; Seyhan A; Oral Yilmaztepe A; Ata B
    Hum Reprod; 2013 Aug; 28(8):2140-5. PubMed ID: 23624580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.